Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by StrikingMooseon Mar 20, 2018 1:01pm

273 Views

Post# 27747403

RE:RE:price predictions?

Yea I can't see myself, as tempting as it is, selling right now for what could be fractions of what they are worth in 12 months or so.

Will be even more painful holding a big fat sack of profits for a whole year than it was holding a sack of my original money waiting for the results.

The temptations are strong lol. But seeing that Wallace is ALREADY travelling accross the globe. Are you kidding me! If he receives an offer for licensing or sale they'd have to halt an inform investors. It could be getting bonkers here, very soon.

Bullboard Posts

Morning Market Outlook for Nov. 15, 2024